Top > Search of International Patents > PEPTIDE VACCINE USING MIMIC MOLECULE OF AMYLOID .beta.-PEPTIDE

PEPTIDE VACCINE USING MIMIC MOLECULE OF AMYLOID .beta.-PEPTIDE

Foreign code F110002711
File No. S2007-1194-C0
Posted date Apr 8, 2011
Country WIPO
International application number 2008JP069586
International publication number WO 2009/054537
Date of international filing Oct 22, 2008
Date of international publication Apr 30, 2009
Priority data
  • P2007-277638 (Oct 25, 2007) JP
Title PEPTIDE VACCINE USING MIMIC MOLECULE OF AMYLOID .beta.-PEPTIDE
Abstract In the invention, a peptide capable of inducing production of an antibody specific to abnormal amyloid .beta.-peptide is found from mimic peptides of amyloid .beta.-peptide and the resulting peptide is used as a vaccine or an immunogen. The invention relates to a pharmaceutical composition comprising a peptide having 8 to 30 amino acid residues containing at least one amino acid sequence of an amino acid sequence represented by the following formula (I): Tyr-Gly-Thr-Lys-Pro-Trp-Met (I) and an amino acid sequence represented by the following formula (II): Leu-Asp-Ile-Phe-Ala-Pro-Ile (II) or a conjugate of the peptide and a carrier.
Scope of claims (In Japanese)
【請求項1】次式(I):Tyr-Gly-Thr-Lys-Pro-Trp-Met (I)で示されるアミノ酸配列、及び次式(II):Leu-Asp-Ile-Phe-Ala-Pro-Ile (II)で示されるアミノ酸配列の少なくとも1つのアミノ酸配列を含む、アミノ酸残基数8~30のペプチド、又は該ペプチドと担体との結合物を含有する医薬組成物。

【請求項2】次式(Ia):Cys-Tyr-Gly-Thr-Lys-Pro-Trp-Met-Cys (Ia)(式中、2つのシステイン残基は架橋されていてもよい。)で示されるアミノ酸配列、次式(Ib):Ser-Tyr-Gly-Thr-Lys-Pro-Trp-Met-Ser-Gly (Ib)で示されるアミノ酸配列、及び次式(IIa):Gly-Met-Leu-Asp-Ile-Phe-Ala-Pro-Ile-Arg-His-Val (IIa)で示されるアミノ酸配列の少なくとも1つのアミノ酸配列を含む、アミノ酸残基数9~30のペプチド、又は該ペプチドと担体との結合物を含有する請求項1記載の医薬組成物。

【請求項3】前記ペプチドが、前記アミノ酸配列と、次式:Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Argで示されるTAT配列とを含む、アミノ酸残基数20~30のペプチドである請求項1又は2記載の医薬組成物。

【請求項4】更にアジュバントを含有する請求項1~3のいずれか1項に記載の医薬組成物。

【請求項5】アミロイドβ線維化阻害剤である請求項1~4のいずれか1項に記載の医薬組成物。

【請求項6】アルツハイマー病の予防・治療剤である請求項1~5のいずれか1項に記載の医薬組成物。

【請求項7】次式(I):Tyr-Gly-Thr-Lys-Pro-Trp-Met (I)で示されるアミノ酸配列、及び次式(II):Leu-Asp-Ile-Phe-Ala-Pro-Ile (II)で示されるアミノ酸配列の少なくとも1つのアミノ酸配列を含む、アミノ酸残基数8~30のペプチド、又は該ペプチドと担体との結合物からなる免疫原。

【請求項8】次式(Ia):Cys-Tyr-Gly-Thr-Lys-Pro-Trp-Met-Cys (Ia)(式中、2つのシステイン残基は架橋されていてもよい。)で示されるアミノ酸配列、次式(Ib):Ser-Tyr-Gly-Thr-Lys-Pro-Trp-Met-Ser-Gly (Ib)で示されるアミノ酸配列、及び次式(IIa):Gly-Met-Leu-Asp-Ile-Phe-Ala-Pro-Ile-Arg-His-Val (IIa)で示されるアミノ酸配列の少なくとも1つのアミノ酸配列を含む、アミノ酸残基数9~30のペプチド、又は該ペプチドと担体との結合物からなる請求項7記載の免疫原。

【請求項9】前記ペプチドが、前記アミノ酸配列と、次式:Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Argで示されるTAT配列とを含む、アミノ酸残基数20~30のペプチドである請求項7又は8記載の免疫原。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KAGOSHIMA UNIVERSITY
  • Inventor
  • SUGIMURA, Kazuhisa
IPC(International Patent Classification)
Specified countries AE(UTILITY MODEL),AG,AL(UTILITY MODEL),AM(PROVISIONAL PATENT)(UTILITY MODEL),AO(UTILITY MODEL),AT(UTILITY MODEL),AU,AZ(UTILITY MODEL),BA,BB,BG(UTILITY MODEL),BH(UTILITY MODEL),BR(UTILITY MODEL),BW(UTILITY MODEL),BY(UTILITY MODEL),BZ(UTILITY MODEL),CA,CH,CN(UTILITY MODEL),CO(UTILITY MODEL),CR(UTILITY MODEL),CU(INVENTOR'S CERTIFICATE),CZ(UTILITY MODEL),DE(UTILITY MODEL),DK(UTILITY MODEL),DM(UTILITY MODEL),DO(UTILITY MODEL),DZ,EC(UTILITY MODEL),EE(UTILITY MODEL),EG(UTILITY MODEL),ES(UTILITY MODEL),FI(UTILITY MODEL),GB,GD,GE(UTILITY MODEL),GH(UTILITY CERTIFICATE),GM,GT(UTILITY MODEL),HN,HR(CONSENSUAL PATENT),HU(UTILITY MODEL),ID,IL,IN,IS,JP(UTILITY MODEL),KE(UTILITY MODEL),KG(UTILITY MODEL),KM,KN,KP(INVENTOR'S CERTIFICATE)(UTILITY MODEL),KR(UTILITY MODEL),KZ(PROVISIONAL PATENT)(UTILITY MODEL),LA,LC,LK,LR,LS(UTILITY MODEL),LT,LU,LY,MA,MD(UTILITY MODEL),ME(PETTY PATENT),MG,MK,MN,MW,MX(UTILITY MODEL),MY(UTILITY-INNOVATION),MZ(UTILITY MODEL),NA,NG,NI(UTILITY MODEL),NO,NZ,OM(UTILITY MODEL),PG,PH(UTILITY MODEL),PL(UTILITY MODEL),PT(UTILITY MODEL),RO,RS(PETTY PATENT),RU(UTILITY MODEL),SC,SD,SE,SG,SK(UTILITY MODEL),SL(UTILITY MODEL),SM,ST,SV(UTILITY MODEL),SY,TJ(UTILITY MODEL),TM(PROVISIONAL PATENT),TN,TR(UTILITY MODEL),TT(UTILITY CERTIFICATE),TZ,UA(UTILITY MODEL),UG(UTILITY CERTIFICATE),US,UZ(UTILITY MODEL),VC(UTILITY CERTIFICATE),VN(PATENT FOR UTILITY SOLUTION),ZA,ZM,ZW,EP(AT,BE,BG,CH,CY,CZ,DE,DK,EE,ES,FI,FR,GB,GR,HR,HU,IE,IS,IT,LT,LU,LV,MC,MT,NL,NO,PL,PT,RO,SE,SI,SK,TR),OA(BF(UTILITY MODEL),BJ(UTILITY MODEL),CF(UTILITY MODEL),CG(UTILITY MODEL),CI(UTILITY MODEL),CM(UTILITY MODEL),GA(UTILITY MODEL),GN(UTILITY MODEL),GQ(UTILITY MODEL),GW(UTILITY MODEL),ML(UTILITY MODEL),MR(UTILITY MODEL),NE(UTILITY MODEL),SN(UTILITY MODEL),TD(UTILITY MODEL),TG(UTILITY MODEL)),AP(BW(UTILITY MODEL),GH(UTILITY MODEL),GM(UTILITY MODEL),KE(UTILITY MODEL),LS(UTILITY MODEL),MW(UTILITY MODEL),MZ(UTILITY MODEL),NA(UTILITY MODEL),SD(UTILITY MODEL),SL(UTILITY MODEL),SZ(UTILITY MODEL),TZ(UTILITY MODEL),UG(UTILITY MODEL),ZM(UTILITY MODEL),ZW(UTILITY MODEL)),EA(AM,AZ,BY,KG,KZ,MD,RU,TJ,TM)
Please contact us by E-mail if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close